 |
[Alpha Biz=(Chicago) Reporter Paul Lee] YuYu Pharma failed to secure more than originally aimed results in Phase I and II clinical trials in the United States of YP-P10, a new drug for dry eye syndrome. The primary evaluation indicators, keratitis color index and eye discomfort, did not differ statistically from the placebo injection group.
YuYu Pharma announced the results of Phase I and II clinical trials in the United States of YP-P10, a treatment for dry eye syndrome, conducted on 257 patients at seven hospitals in the United States.
As a result of the test, YP-P10 improved some of the primary evaluation indicators, "Total Corneal Fluorescein Staining Scores" (total corneal color index) and "ODS" (Ocular Discomfort Scores) in the 12th week, at the end of phase 1 and 2 clinical administration, but did not secure statistical significance compared to the stomach group.
However, YP-P10 showed a statistically significant increase in tear secretion compared to placebo after administration in one of the second evaluation indexes, the Schirmer test. While the tear secretion of existing dry eye treatments was three to six months, the tear secretion of YP-P10 appeared in 15 days.
Yuyu Pharmaceutical plans to establish a future R&D direction after the first analysis of the clinical trial results with the New Drug Development Advisory Group.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
